Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor vs Clopidogrel Effect on MFR in CAD Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years old~2. Stable coronary artery disease on stable medical treatment.~3. BMI equal to or less than 30 kg/m2~4. No clinically significant abnormalities in baseline laboratory work~5. No clinically significant arrhythmias on baseline 12-lead electrocardiogram~6. Female subjects must be post-menopausal, surgically sterilized or have negative urine beta human chorionic gonadotropin pregnancy test at initial screening and maintain effective contraceptive methods throughout the trial and for 7 days following the end of dosing treatment.~Exclusion Criteria:~1. Any contraindication against the use of clopidogrel, ticagrelor and/or ASA.~2. Oral anticoagulation therapy.~3. History of intracranial bleeding.~4. Recent or active pathological bleeding, such as peptic ulcer.~5. Moderate or severe hepatic impairment.~6. History or risk of bradycardia.~7. Known second- or third-degree AV block without pacemaker~8. Dyspnea (NYHA III/IV), wheezing asthma or COPD.~9. Coronary artery bypass graft (CABG) surgery within 90 days prior to screening or at any time after consent.~10. Percutaneous coronary intervention (PCI) within 90 days prior to screening or at any time following consent.~11. Acute myocardial infarction or acute coronary syndrome within 60 days prior to screening or at any time following consent.~12. Any scheduled surgery during the trial period, including dental.~13. Concomitant therapy with strong cytochrome CYP 3A inhibitor or inducer.~14. Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox)~15. Known hypersensitivity to the investigational drug or any of its components.~16. Known hypersensitivity to adenosine.~17. Lactose intolerance~18. Breastfeeding or pregnancy.~19. Claustrophobia or inability to lie still in a supine position~20. Unwillingness to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- stable CAD management (Type: EXPERIMENTAL): Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day
- CAD comparison group (Type: ACTIVE_COMPARATOR): Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).